Review supports post-PCI use of dual antiplatelet therapy

07/10/2013 | Healio

Data review found dual antiplatelet therapy is the mainstay treatment for reducing cardiovascular risks after percutaneous coronary intervention, according to researchers from the University of Texas Southwestern Medical Center. The study, published in the Journal of the American Medical Association, recommended the low-dose aspirin component be continued indefinitely and a P2Y12 inhibitor should be prescribed for 12 months except in patients at high risk for bleeding.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA